By Patricia Inácio, PhD on 12/20/2022
Researchers have developed a new therapy that reduced the toxic buildup of the mutant huntingtin (HTT) protein — the hallmark of Huntington’s disease — in lab-grown neurons from Huntington’s patients and in a mouse model of the disease. The CRISPR-based therapy was designed to specifically target the HTT gene’s messenger RNA (mRNA), the blueprint molecule derived […]
The post New RNA-targeting Therapy Reduces Toxic HTT Protein Buildup appeared first on Huntington's Disease News.
|